GPX4-IN-19

Overview

GPX4-IN-19 is an effective GPX4 inhibitor ( IC 50 = 0.311 μM), covalently binds to the Sec 46 site of GPX4. GPX4-IN-19 shows strong anti-proliferative activity with high ferroptosis selectivity. GPX4-IN-19 causes intracellular Fe 2+ accumulation, leading to increased levels of lipid peroxides (LPOs) and reactive oxygen species (ROS) , which induces ferroptosis and subsequently results in DNA damage . GPX4-IN-19 can be used for the study of Triple-Negative Breast Cancer (TNBC).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > Glutathione Peroxidase | Products > Signaling Pathways > Ferroptosis | Products > Signaling Pathways > Lipoxygenase

Product Information

• Catalog No.: HY-178364
• CAS No.: 3102894-57-2
• Molecular Formula: C19H19ClFNO5
• Molecular Weight: 395.81
• Purity: 99.45%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source